Literature DB >> 7859351

Chemoprevention of 2-amino-1-methyl-6-phenylimidazo[4,5-b]-pyridine (PhIP)-induced mammary gland carcinogenesis by antioxidants in F344 female rats.

M Hirose1, K Akagi, R Hasegawa, M Yaono, T Satoh, Y Hara, K Wakabayashi, N Ito.   

Abstract

Chemopreventive effects of the antioxidants 1-O-hexyl-2,3,5- trimethylhydroquinone (HTHQ), 3-O-ethylascorbic acid (EAsA), 3-O-dodecylcarbomethylascorbic acid (DAsA), green tea catechins (GTC) and ellagic acid on 2-amino-1-methyl-6- phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary carcinogenesis were examined in female F344 rats. Groups of 20-21 6-week-old rats were maintained on a powdered diet containing 0.02% PhIP alone, PhIP together with 0.5% HTHQ, 1% EAsA, 1% DAsA, 1% GTC or 0.1% ellagic acid, these antioxidants alone or basal diet alone without supplement for 52 weeks. The survival rates of PhIP plus antioxidant groups at the end of the experiment were higher than that of the PhIP alone group. Sequential observation of palpable mammary tumors demonstrated only one tumor by week 52 in the PhIP plus HTHQ group, whereas 40% of the rats receiving PhIP alone had tumors by this time point. The final incidence of mammary adenocarcinomas was significantly decreased in the PhIP plus HTHQ group (4.8%, P < 0.01) as compared to the PhIP alone value (40%). Although statistically not significant, incidences of adenocarcinomas in the other antioxidant-treated groups (23.8-28.6%) were also lower than in the PhIP alone group. Furthermore, the incidence of large intestinal tumors in the PhIP plus HTHQ group (0%) showed a tendency to decrease relative to the PhIP alone group (16.7%). These results indicate that antioxidants, particularly HTHQ, exert a potent chemopreventive action against PhIP-induced carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7859351     DOI: 10.1093/carcin/16.2.217

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  Delphinidin Inhibits HER2 and Erk1/2 Signaling and Suppresses Growth of HER2-Overexpressing and Triple Negative Breast Cancer Cell Lines.

Authors:  Tuba Ozbay; Rita Nahta
Journal:  Breast Cancer (Auckl)       Date:  2011-07-12

2.  Organ-dependent modifying effects of caffeine, and two naturally occurring antioxidants alpha-tocopherol and n-tritriacontane-16,18-dione, on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)-induced mammary and colonic carcinogenesis in female F344 rats.

Authors:  A Hagiwara; P Boonyaphiphat; H Tanaka; M Kawabe; S Tamano; H Kaneko; M Matsui; M Hirose; N Ito; T Shirai
Journal:  Jpn J Cancer Res       Date:  1999-04

3.  Inhibitory effects of diallyl disulfide or aspirin on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary carcinogenesis in rats.

Authors:  N Suzui; S Sugie; K M Rahman; M Ohnishi; N Yoshimi; K Wakabayashi; H Mori
Journal:  Jpn J Cancer Res       Date:  1997-08

4.  Effects of antioxidant 1-O-hexyl-2,3,5-trimethylhydroquinone or ascorbic acid on carcinogenesis induced by administration of aminopyrine and sodium nitrite in a rat multi-organ carcinogenesis model.

Authors:  Hideaki Yada; Masao Hirose; Seiko Tamano; Mayumi Kawabe; Masashi Sano; Satoru Takahashi; Mitsuru Futakuchi; Tokutaro Miki; Tomoyuki Shirai
Journal:  Jpn J Cancer Res       Date:  2002-12

5.  Inhibitory Effect of 1-O-Hexyl-2,3,5-Trimethylhydroquinone on Dimethylnitrosamine-induced Liver Fibrosis in Male SD Rats.

Authors:  Yu-Ri Jung; Young-Jung Lee; Nam-Jin Lee; Chun-Mai Lin; Jun-Hawn Moon; Hee-Yul Chai; Jong-Koo Kang
Journal:  Toxicol Res       Date:  2010-09

6.  Dose dependence of 1-O-hexyl-2,3,5-trimethylhydroquinone promotion of forestomach carcinogenesis in rats pretreated with N-ethylnitrosourethane.

Authors:  Y Mizoguchi; M Hirose; T Yamaguchi; P Boonyaphiphat; T Miki; T Shirai
Journal:  Jpn J Cancer Res       Date:  1998-05

7.  Dose-dependent induction of 8-hydroxyguanine and preneoplastic foci in rat liver by a food-derived carcinogen, 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline, at low dose levels.

Authors:  T Kato; R Hasegawa; D Nakae; M Hirose; M Yaono; L Cui; Y Kobayashi; Y Konishi; N Ito; T Shirai
Journal:  Jpn J Cancer Res       Date:  1996-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.